200 related articles for article (PubMed ID: 25535978)
61. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
62. [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Zhou RQ; Gong YP; Zheng BH; Yang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):789-92. PubMed ID: 21302442
[TBL] [Abstract][Full Text] [Related]
63. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.
Hsieh AC; Costa M; Zollo O; Davis C; Feldman ME; Testa JR; Meyuhas O; Shokat KM; Ruggero D
Cancer Cell; 2010 Mar; 17(3):249-61. PubMed ID: 20227039
[TBL] [Abstract][Full Text] [Related]
64. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
[TBL] [Abstract][Full Text] [Related]
65. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
66. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
67. Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.
Siska PJ; van der Windt GJ; Kishton RJ; Cohen S; Eisner W; MacIver NJ; Kater AP; Weinberg JB; Rathmell JC
J Immunol; 2016 Sep; 197(6):2532-40. PubMed ID: 27511728
[TBL] [Abstract][Full Text] [Related]
68. Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells.
Puli S; Jain A; Lai JC; Bhushan A
Neurochem Res; 2010 Jul; 35(7):986-93. PubMed ID: 20177775
[TBL] [Abstract][Full Text] [Related]
69. The effect of fludrocortisone on the uterine receptivity partially mediated by ERK1/2-mTOR pathway.
Hesam Shariati MB; Seghinsara AM; Shokrzadeh N; Niknafs B
J Cell Physiol; 2019 Nov; 234(11):20098-20110. PubMed ID: 30968418
[TBL] [Abstract][Full Text] [Related]
70. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
Yang C; Huang X; Liu H; Xiao F; Wei J; You L; Qian W
Oncotarget; 2017 Jun; 8(24):39185-39197. PubMed ID: 28402933
[TBL] [Abstract][Full Text] [Related]
71. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
72. Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.
Kosciuczuk EM; Saleiro D; Platanias LC
Cytokine; 2017 Jan; 89():116-121. PubMed ID: 27094611
[TBL] [Abstract][Full Text] [Related]
73. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
Willems L; Chapuis N; Puissant A; Maciel TT; Green AS; Jacque N; Vignon C; Park S; Guichard S; Herault O; Fricot A; Hermine O; Moura IC; Auberger P; Ifrah N; Dreyfus F; Bonnet D; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Leukemia; 2012 Jun; 26(6):1195-202. PubMed ID: 22143671
[TBL] [Abstract][Full Text] [Related]
74. N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells.
Wang M; Zhou A; An T; Kong L; Yu C; Liu J; Xia C; Zhou H; Li Y
J Exp Clin Cancer Res; 2016 Mar; 35():41. PubMed ID: 26940018
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of Insulin-mediated Regulation of AKT Signaling in Childhood Acute Lymphoblastic Leukemia.
Wang J; Xue HM; Chen YR; Xu HG; Lin SF; Tang XK; Chen C
J Pediatr Hematol Oncol; 2019 Mar; 41(2):96-104. PubMed ID: 30688831
[TBL] [Abstract][Full Text] [Related]
76. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
[TBL] [Abstract][Full Text] [Related]
77. Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.
Liang S; Guo R; Zhang Z; Liu D; Xu H; Xu Z; Wang X; Yang L
Oncol Rep; 2013 Jun; 29(6):2422-30. PubMed ID: 23588929
[TBL] [Abstract][Full Text] [Related]
78. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
79. Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study.
Feng H; Yang Z; Bai X; Yang M; Fang Y; Zhang X; Guo Q; Ning H
Int J Mol Med; 2018 Apr; 41(4):2099-2107. PubMed ID: 29344639
[TBL] [Abstract][Full Text] [Related]
80. Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model.
Salama M; Elhussiny M; Magdy A; Omran AG; Alsayed A; Ashry R; Mohamed W
Metab Brain Dis; 2018 Apr; 33(2):583-587. PubMed ID: 29080085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
